Intellia Therapeutics Inc (NASDAQ:NTLA) price on Thursday, May 01, fall -2.59% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $8.64.
A look at the stock’s price movement, the close in the last trading session was $8.87, moving within a range at $8.495 and $8.9. The beta value (5-Year monthly) was 2.227. Turning to its 52-week performance, $28.18 and $5.90 were the 52-week high and 52-week low respectively. Overall, NTLA moved 29.83% over the past month.
Intellia Therapeutics Inc’s market cap currently stands at around $894.39 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-26.
The average forecast suggests down to a -58.58% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 49.27M, representing a -14.88% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that NTLA is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
13 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 13 recommend NTLA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
NTLA’s current price about 14.02% and -0.57% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 55.72, while 7-day volatility ratio is 7.03% and 9.76% in the 30-day chart. Further, Intellia Therapeutics Inc (NTLA) has a beta value of 2.33, and an average true range (ATR) of 0.67. Analysts have given the company’s stock an average 52-week price target of $26, forecast between a low of $9 and high of $60. Looking at the price targets, the low is -4.17% off current price level while to achieve the yearly target high, price needs to move -594.44%. Nonetheless, investors will most likely welcome a -200.93% jump to $26 which is the analysts’ median price.
If we refocus on Intellia Therapeutics Inc (NASDAQ:NTLA), historical trading data shows that trading volumes averaged 2.97 over the past 10 days and 3.43 million over the past 3 months. The company’s latest data on shares outstanding shows there are 102.03 million shares.
The 5.89% of Intellia Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 92.58% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 28.51 million on 2025-04-15, giving us a short ratio of 7.57. The data shows that as of 2025-04-15 short interest in Intellia Therapeutics Inc (NTLA) stood at 3130.0 of shares outstanding, with shares short rising to 26.69 million registered in 2025-03-14. Current price change has pushed the stock -25.90% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the NTLA stock continues to rise going into the next quarter.
